Previous 10 | Next 10 |
home / stock / ipsef / ipsef news
Total-sales growth in FY 2023 of 6.7% at CER 1 (3.4% as reported) included strong sales from the growth platforms 2 and good contributions from the new medicines. A core operating margin of 32.0% (IFRS operating margin of 26.1%), based on further enrichment of the pipeline and accelerated...
2023-12-19 09:10:24 ET Summary Mirum Pharmaceuticals, Inc. stock dropped 16% after its lead asset, Livmarli, failed to meet primary or secondary endpoints in a phase 2 trial for biliary atresia. This looks like an overreaction considering the small addressable market and no negati...
2023-12-12 10:33:17 ET More on AbbVie, Evolus, etc. AbbVie: 4 Hidden Keys Investors Must Know To Judge ImmunoGen Acquisition AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time AbbVie: $10 Billion Cancer Deal To Boost Growth AbbVie upgraded at Goldman ...
PARIS, FRANCE, 7 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K. “Ipsen has made significant progress since our strategic roadmap was implemented three years ago and is today...
New Drug Application granted priority review with PDUFA date set for June 10, 2024 European Medicines Agency (EMA) has also validated the Marketing Authorization Application (MAA) for elafibranor Investigational elafibranor is the first novel second-line treatment for primary bili...
ELATIVE ® Phase III trial confirms potential for investigational elafibranor as a novel, first-in-class, dual PPAR α,δ agonist for patients with primary biliary cholangitis. Elafibranor demonstrates significant improvements in biomarkers of disease progression versu...
2023-10-26 03:55:25 ET More on Ipsen S.A., Ipsen S.A., etc. Exelixis lead product hits main goal in Phase 3 prostate cancer trial Ipsen wins FDA approval of rare bone disease drug palovarotene Historical earnings data for Ipsen S.A. Dividend scorecard for Ips...
Paris (France), 26 October 2023 Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today presents its sales performance for the year to date and the third quarter of 2023. Sales and pipeline highlights Total-sales growth in the year to da...
Positive opinion from Committee for Medicinal Products for Human Use recommending approval of Bylvay ® (odevixibat) based on Phase III ASSERT clinical-trial data in Alagille syndrome (ALGS) already received in July 2023 Committee for Orphan Medicinal Products confirms a negative ...
PARIS, FRANCE, 3 October 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its partner Galderma has confirmed receipt from the FDA of a Complete Response Letter related to its Biologics License Application for liquid botulinum toxin type A (QM-1114), noting certain deficienci...
News, Short Squeeze, Breakout and More Instantly...
Ipsen Sa Ord Company Name:
IPSEF Stock Symbol:
OTCMKTS Market:
PARIS, FRANCE, 2 May 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024. She will serve on the Executive Leadership Team (ELT) and report dire...
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. Highlights Total-sales growth of 13.3% at CER 1 , or 10.9% as reported, driven by the 16.2% ...
Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development candidate validation, Ipsen will assume responsibility for further development and commercialization, leveraging existing neuroscience expertise...